RxDoctor Payments Data

Kevin McKnight, MD

Rheumatology · Pine Knoll Shores, NCNPI 1598773343

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 63 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$706
  • UCB, Inc.$174
  • Ironshore Pharmaceuticals Inc.$130
  • Johnson & Johnson$101
  • Amgen$93
  • Takeda Pharmaceuticals U.S.A., Inc.$69
  • plus $136 from 6 others

What the payments were for

  • Food & beverage$1,39699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 35th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$46,188
Medicare patients
85
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab17$122,613
RinvoqUpadacitinib15$92,632
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl245$60,634
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$7,414
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen86$4,364
Hydroxychloroquine Sulfate85$3,316
Celecoxib85$2,560
Pregabalin39$2,098
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$1,822
Theophylline ErTheophylline Anhydrous19$1,540
Tizanidine Hcl58$1,430
Gabapentin83$1,241
Duloxetine Hcl76$1,040
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$1,002
Methadone Hcl51$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$706$92,63215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Pine Knoll Shores

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →